GlassScriptPhysician profile
Bruce H Schwartz
NPI 1497730261
$3,223.81
in general payments reported to CMS, 2019-2025
21 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $83.62 · 2021: $331 · 2022: $474 · 2023: $525 · 2024: $425 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,015.27 | 2019-2025 | Rocklatan, Argos, Tryptyr |
| Bausch & Lomb Americas INC. | $327.17 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $302.04 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $211.93 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $174.43 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $165.42 | 2019-2021 | |
| Abbvie INC. | $139.60 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.37 | 2019-2021 | |
| Eyepoint US, INC. | $133.42 | 2019 | |
| Aerie Pharmaceuticals, INC. | $124.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $107.70 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $83.82 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $73.85 | 2024-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $65.28 | 2021-2025 | |
| Shire North American Group INC | $31.92 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $31.57 | 2020 | |
| Rayner Intraocular Lenses Limited | $30.82 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
| Thea Pharma INC. | $21.47 | 2025 | Iyuzeh |
| Sight Sciences, INC. | $19.18 | 2021 | |
| Harrow Eye, LLC | $16.15 | 2025 | Vevye |
| Glaukos Corporation | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.